The substituted aminothiazole alpelisib (NVP-BYL719) (28 in Figure 4), by Novartis, is a potent and selective PI3Kα (a member of the PI3K family) inhibitor with IC50 of 5 nM in enzymatic assays and it maintains activity on the oncogenic mutated PI3Kα, that, although found in many tumors, are not very frequent in NB [135]. This evidence concerns the gene PIK3CD and neuroblastoma.